littorine: RN given refers to (3(R)-endo)-isomer; RN for cpd without isomeric designation not avail 3/90; isolated from a Duboisia hybrid
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Duboisia | genus | A plant genus of the family SOLANACEAE that is a source of SCOPOLAMINE and other TROPANES.[MeSH] | Solanaceae | A plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 443005 |
CHEBI ID | 6506 |
SCHEMBL ID | 24475294 |
MeSH ID | M0174461 |
Synonym |
---|
littorine |
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2r)-2-hydroxy-3-phenylpropanoate |
CHEBI:6506 |
8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-3-phenylpropanoate |
DTXSID20944553 |
Q6653346 |
SCHEMBL24475294 |
Littorine is a key biosynthetic intermediate in the hyoscyamine and scopolamine biosynthesis pathways.
Excerpt | Reference | Relevance |
---|---|---|
"Littorine is a key biosynthetic intermediate in the hyoscyamine and scopolamine biosynthetic pathways." | ( Functional genomics analysis reveals two novel genes required for littorine biosynthesis. Chen, M; Huang, JP; Huang, SX; Kai, G; Lan, X; Liao, Z; Qiu, F; Wang, J; Yang, C; Zeng, J; Zhou, W, 2020) | 1.52 |
Class | Description |
---|---|
tropane alkaloid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.67) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 9 (60.00) | 29.6817 |
2010's | 2 (13.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.89) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |